摘要
目的探究将孟鲁斯特钠应用于治疗小儿哮喘中的效果,评价治疗后患儿的不良反应发生率以及复发率。方法在该院中方便选择数据库时间段2016年4月—2018年9月间收入的所有小儿哮喘患儿的一般资料,按照实验要求调取其中84例患儿纳入研究开展实验,通过随机法将所有患儿分为对照组(n=42)与实验组(n=42)。对照组单纯应用布地奈德气雾剂进行治疗,实验组患儿实施布地奈德和孟鲁司特钠联合治疗方案。治疗完成后对所有患儿的治疗临床效果进行评价,同时记录所有患儿的复发状况以及治疗后不良反应发生率。结果该次试验结果显示,实验组患儿在治疗完成后其治疗有效率为95.24%(40/42),对照组患者治疗后的总有效率为80.95%(34/42),差异有统计学意义(χ^2=9.7354,P=0.0018)。同时实验组患者的不良反应发生率为4.76%,其数据低于对照组患者的14.29%,数据对比明显,差异有统计学意义(χ^2=5.2694,P=0.0217),而实验组患者的复发率(2.38%)较对照组(21.43%)来说更低,数据对比差异有统计学意义(χ^2=17.3013,P=0.0000)。结论在对小儿哮喘进行治疗时,应用孟鲁司特钠联合布地奈德进行治疗,能够在保证患儿治疗效果的基础上,降低儿童的不良事件发生率,同时也能够降低患儿治疗后的复发率,具有高度的临床应用价值,值得推广使用。
Objective To investigate the effect of application of montelukast sodium in the treatment of asthma in children,and to evaluate the incidence of adverse reactions and the recurrence rate of children after treatment.Methods In our hospital,we selected convenient general data on all children with asthma in the database from April 2016 to September 2018.According to the experimental requirements,84 patients were included in the study and conducted experiments.All children were divided into control group(n=42)and experimental group(n=42).The control group was treated with budesonide aerosol alone,and the experimental group was treated with budesonide and montelukast sodium.After treatment,the clinical effects of all patients were evaluated,and the recurrence status of all children and the incidence of adverse reactions after treatment were recorded.Results The results of this trial showed that the effective rate of the experimental group was 95.24%(40/42)after the completion of treatment,and the total effective rate after treatment was 80.95%(34/42).The difference was statistically significant(χ^2=9.735 4,P=0.001 8).At the same time,the incidence of adverse reactions in the experimental group was 4.76%,and the data was 14.29%lower than that in the control group.The data were statistically significant,the difference was statistically significant(χ^2=5.269 4,P=0.021 7),and the recurrence rate of the experimental group(2.38%)was lower than the control group(21.43%),and the data contrast was significantly different(χ^2=17.301 3,P=0.000 0).Conclusion In the treatment of pediatric asthma,the application of montelukast sodium combined with budesonide can reduce the incidence of adverse events in children and ensure the treatment of children after treatment.The recurrence rate has a high clinical application value and is worthy of promotion.
作者
高会
GAO Hui(Pediatrics Department,Zaozhuang Mining Group Tengnan Hospital,Jinning,Shandong Province,277606 China)
出处
《中外医疗》
2019年第22期109-111,共3页
China & Foreign Medical Treatment
关键词
布地奈德
孟鲁司特钠
小儿哮喘
临床效果
治疗方案
Budesonide
Montelukast sodium
Pediatric asthma
Clinical effect
Treatment plan
